Endovascular Techniques News Today

An updated expert consensus statement on catheter and surgical ablation of atrial fibrillation offered practical advice on various new tools in the field.

The use of mechanical thrombectomy was associated with short- and long-term improvements in pulmonary hypertension in adults with pulmonary embolism.

New results from the SELECT2 trial also show benefit of the procedure in a large range of ischemic core sizes and in patients transferred from an outside hospital.

Argatroban and eptifibatide were ineffective as adjunctive therapies to thrombolysis in patients with ischemic stroke in the MOST trial.

Edwards Lifesciences received approval for its Evoque tricuspid valve replacement system, the first transcatheter therapy approved in the US for tricuspid regurgitation.

Boston Scientific has received approval for the Farapulse Pulsed Field Ablation system for treatment of drug-refractory, recurrent paroxysmal atrial fibrillation.

The Amulet and Watchman FLX devices for left atrial appendage closure produced equivalent results, with about half of patients having residual patency of the appendage at 13 months, a study shows.

A drug-eluting resorbable scaffold was superior to angioplasty in treating infrapopliteal artery disease and chronic limb-threating ischemia and was noninferior for safety in the LIFE-BTK trial.

Two new studies of the potential neuroprotective agent nerinetide for patients with acute ischemic stroke have shown conflicting results, with suggestions of benefit when given very early in the prehospital setting.

The transcatheter stent-like device diverts arterial flow to the lower-extremity venous system to treat no-option patients with chronic limb-threatening ischemia.